End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
100.50 CHF | +4.75% |
|
+4.25% | +2.84% |
02-11 | DSM-Firmenich to Sell Feed Enzymes Alliance JV Share to Partner for $1.55 Billion | DJ |
02-11 | Novonesis to buy DSM-Firmenich's stake in enzymes venture for $1.6 bln | RE |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 9.01B | 8.11B | 9.2B | 8.39B | 10.63B | |||||
Total Revenues | 9.01B | 8.11B | 9.2B | 8.39B | 10.63B | |||||
Cost of Goods Sold, Total | 5.96B | 5.33B | 6.04B | 5.7B | 8.02B | |||||
Gross Profit | 3.05B | 2.78B | 3.16B | 2.69B | 2.61B | |||||
Selling General & Admin Expenses, Total | 1.8B | 1.62B | 1.79B | 1.77B | 2.54B | |||||
R&D Expenses | 349M | 398M | 323M | 295M | 652M | |||||
Other Operating Expenses | 20M | 84M | 29M | -29M | -16M | |||||
Other Operating Expenses, Total | 2.16B | 2.1B | 2.14B | 2.04B | 3.17B | |||||
Operating Income | 889M | 672M | 1.02B | 652M | -560M | |||||
Interest Expense, Total | -96M | -90M | -92M | -104M | -138M | |||||
Interest And Investment Income | 9M | 17M | 3M | 22M | 95M | |||||
Net Interest Expenses | -87M | -73M | -89M | -82M | -43M | |||||
Income (Loss) On Equity Invest. | -9M | -64M | 16M | 12M | -6M | |||||
Currency Exchange Gains (Loss) | -12M | -22M | -7M | -20M | -86M | |||||
Other Non Operating Income (Expenses) | 4M | 14M | -15M | -1M | -26M | |||||
EBT, Excl. Unusual Items | 785M | 527M | 928M | 561M | -721M | |||||
Restructuring Charges | - | - | - | - | - | |||||
Merger & Related Restructuring Charges | -11M | -55M | -25M | -3M | -59M | |||||
Gain (Loss) On Sale Of Investments | 63M | 32M | 326M | -7M | -1M | |||||
Gain (Loss) On Sale Of Assets | 7M | - | 13M | 31M | 17M | |||||
Asset Writedown | - | - | - | - | - | |||||
Insurance Settlements | 16M | 29M | 11M | 12M | 53M | |||||
Legal Settlements | 8M | 23M | 2M | - | - | |||||
Other Unusual Items | 48M | 7M | 2M | 5M | 57M | |||||
EBT, Incl. Unusual Items | 916M | 563M | 1.26B | 599M | -654M | |||||
Income Tax Expense | 152M | 106M | 168M | 124M | -18M | |||||
Earnings From Continuing Operations | 764M | 457M | 1.09B | 475M | -636M | |||||
Earnings Of Discontinued Operations | - | 51M | 591M | 1.24B | 2.79B | |||||
Net Income to Company | 764M | 508M | 1.68B | 1.72B | 2.15B | |||||
Minority Interest | -6M | -2M | -4M | -15M | -16M | |||||
Net Income - (IS) | 758M | 506M | 1.68B | 1.7B | 2.14B | |||||
Preferred Dividend and Other Adjustments | 8M | 7M | 6M | 6M | 6M | |||||
Net Income to Common Incl Extra Items | 750M | 499M | 1.67B | 1.69B | 2.13B | |||||
Net Income to Common Excl. Extra Items | 750M | 448M | 1.08B | 454M | -658M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 4.27 | 2.91 | 9.67 | 9.8 | 9.14 | |||||
Basic EPS - Continuing Operations | 4.27 | 2.61 | 6.25 | 2.63 | -2.82 | |||||
Basic Weighted Average Shares Outstanding | 176M | 172M | 173M | 173M | 233M | |||||
Net EPS - Diluted | 4.24 | 2.89 | 9.63 | 9.77 | 9.14 | |||||
Diluted EPS - Continuing Operations | 4.24 | 2.59 | 6.22 | 2.61 | -2.82 | |||||
Diluted Weighted Average Shares Outstanding | 177M | 172M | 173M | 173M | 233M | |||||
Normalized Basic EPS | 2.76 | 1.91 | 3.34 | 1.94 | -2 | |||||
Normalized Diluted EPS | 2.74 | 1.9 | 3.32 | 1.94 | -2 | |||||
Dividend Per Share | 2.4 | 2.4 | 2.5 | 2.53 | 0.93 | |||||
Payout Ratio | 38.39 | 57.11 | 15.87 | 20.29 | 7.35 | |||||
American Depositary Receipts Ratio (ADR) | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | |||||
Supplemental Items | ||||||||||
EBITDA | 1.38B | 1.21B | 1.62B | 1.23B | 352M | |||||
EBITA | 1.04B | 865M | 1.24B | 892M | -83M | |||||
EBIT | 889M | 672M | 1.02B | 652M | -560M | |||||
Effective Tax Rate - (Ratio) | 16.59 | 18.83 | 13.37 | 20.7 | 2.75 | |||||
Total Current Taxes | 91M | 145M | 122M | 107M | 188M | |||||
Total Deferred Taxes | 61M | -39M | 46M | 17M | -206M | |||||
Normalized Net Income | 485M | 327M | 576M | 336M | -467M | |||||
Interest Capitalized | 3M | 6M | 4M | 3M | 4M | |||||
Interest on Long-Term Debt | 7M | 6M | 5M | 6M | 8M | |||||
Non-Cash Pension Expense | -9M | 4M | -7M | 1M | 7M | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | 1.26B | 1.15B | 1.27B | 1.24B | 1.51B | |||||
General and Administrative Expenses | 525M | 469M | 517M | 534M | 1.02B | |||||
Research And Development Expense From Footnotes | 396M | 507M | 334M | 295M | 652M | |||||
Stock-Based Comp., Other (Total) | 34M | 29M | 22M | 35M | 29M | |||||
Total Stock-Based Compensation | 34M | 29M | 22M | 35M | 29M |